The Pharmaceutical Journal15 FEB 2016
Roundworm study shows bexarotene could inhibit early step of amyloid-beta aggregation.
A major therapeutic strategy for the prevention of Alzheimer’s disease is to inhibit the assembly of the disordered amyloid-beta peptide that aggregates in the brain. But no clinical trial to date has succeeded in this aim.
In a previous study, researchers at the University of Cambridge identified some of the underlying molecular events that lead to amyloid-beta aggregation. Using this information, the team have now found that in a roundworm model, the anti-cancer drug bexarotene could inhibit the earliest step of the process and delay the formation of the most toxic form of amyloid-beta aggregates. But only if bexarotene is administered early.
Reporting their findings in Science Advances (12 February 2016), the team suggest that in future, drugs like bexarotene could be classed as ‘neurostatins’ and used in a preventive manner similar to statins for heart disease.
Citation: The Pharmaceutical JournalDOI: 10.1211/CP.2016.20200696